(3S,5S)-3-Isopropyl-5-((2S,4S)-4-Isopropyl-5-Oxotetrahydro-Furan-2-Yl)-2-Oxopyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

Production-scale handling of (3S,5S)-3-Isopropyl-5-((2S,4S)-4-Isopropyl-5-Oxotetrahydro-Furan-2-Yl)-2-Oxopyrrolidine-1-Carboxylic Acid Tert-Butyl Ester confirms a narrow thermal processing window: differential scanning calorimetry per ASTM E1356-23 records a sharp melt endotherm at 112–114°C with decomposition onset detectable at 168°C via thermogravimetric analysis, limiting hot-melt processing to temperatures at least 45°C below the decomposition threshold. The Boc-protected pyrrolidinone-lactone scaffold, bearing two pendant isopropyl groups on chiral centers at C-3 and the γ-lactone ring, exhibits solubility exceeding 280 mg/mL in anhydrous tetrahydrofuran at 25°C while dropping to 4.2 mg/mL in deionized water, a partition coefficient that governs its behavior in biphasic reaction systems. Residual palladium content, a critical quality attribute when the compound is synthesized via Pd-catalyzed cross-coupling routes, is routinely controlled to <10 ppm as measured by inductively coupled plasma mass spectrometry (USP <233>), while enantiomeric excess is verified above 99.5% by chiral supercritical fluid chromatography with a detection wavelength of 210 nm. The tertiary-butyl carbamate moiety undergoes clean thermolytic deprotection at 140–150°C in the presence of 1.0–1.5 eq of p-toluenesulfonic acid monohydrate in refluxing dichloromethane, a transformation monitored by inline ReactIR to confirm disappearance of the Boc carbonyl stretch at 1714 cm⁻¹.

Vacuum-dried material stored under nitrogen in HDPE drums with PTFE-lined closures at 2–8°C demonstrates 24-month shelf stability with less than 0.3% total related substances when protected from moisture ingress above 40% relative humidity. Exposure to ambient laboratory conditions at 25°C/60% RH for 72 hours generates 1.8% de-Boc byproduct, as quantified by HPLC at 254 nm against a certified reference standard, underscoring the necessity of dry inert atmosphere during dispensing and weighing operations conducted on production floors. The stereochemical integrity at the four chiral centers is preserved provided the material is not subjected to pH environments below 2.0 or above 10.5 in aqueous-organic cosolvent systems, a boundary established through accelerated degradation studies at 40°C/75% RH conducted over 6 weeks in accordance with ICH Q1A(R2).

Does the stereochemical array survive long-duration continuous flow hydrogenation conditions?

In the asymmetric hydrogenation of prochiral enamides to chiral amine intermediates destined for HIV protease inhibitor synthesis, this Boc-protected chiral auxiliary is introduced at 1.1–1.3 mol% relative to the substrate in a continuous stirred-tank reactor train operating under 18–22 bar hydrogen pressure. Regulatory compliance falls under ICH M7(R2) for mutagenic impurity control, with the nitrosamine risk assessment conducted per EMA/409815/2020 owing to the tertiary-butyl carbamate's potential to generate N-nitrosamine species in the presence of nitrite residues carried over from quenching operations. The compound is pre-dissolved in degassed toluene (0.12 M) and co-fed with the enamide substrate stream into a 316L stainless steel fixed-bed reactor packed with Rh-DuPhos on carbon at a weight hourly space velocity of 0.8 h⁻¹. Process analytical technology—specifically on-line Raman spectroscopy monitoring the enamide C=C stretch at 1630 cm⁻¹—provides real-time conversion data, enabling closed-loop adjustment of the auxiliary:substrate molar ratio within ±0.02 eq to maintain enantioselectivity above 96% ee. The finished chiral amine hydrochloride salt, isolated after Boc deprotection with 4M HCl in dioxane at 0–5°C followed by crystallization from isopropanol/MTBE, enters the downstream peptide coupling sequence for atazanavir sulfate bulk drug substance production. A documented operational boundary limits cumulative reactor residence time to ≤4 hours; beyond this threshold, epimerization at the α-position increases by approximately 0.4% ee/hour based on batch record data from 14 consecutive commercial campaigns executed in 1000 L glass-lined hydrogenation vessels.

When lactone ring-opening competes with pyrrolidinone N-alkylation in phase-transfer catalysis

The manufacturing route for the hepatitis C NS3/4A protease inhibitor grazoprevir deploys this lactone-fused pyrrolidinone as an electrophilic chiral building block in a biphasic N-alkylation step, wherein the γ-lactone ring undergoes potassium carbonate-mediated opening at the acyl-oxygen bond while the pyrrolidinone nitrogen is simultaneously functionalized with an allylic bromide in a dichloromethane/50% aqueous KOH system containing tetrabutylammonium hydrogen sulfate at 5 mol%. The formulation charge ratio is specified as 1.0 eq substrate to 2.2 eq potassium carbonate to 1.05 eq allylic bromide, a delicate stoichiometric balance established through factorial design-of-experiments optimization that identified excessive base loading as the primary driver of premature Boc cleavage via hydroxide attack at the carbamate carbonyl. Compliance with ICH Q3C(R8) residual solvent limits requires gas chromatography headspace confirmation that dichloromethane is below 600 ppm and MTBE below 5000 ppm in the isolated intermediate prior to advancing to the subsequent macrolactamization. The downstream production sequence involves diluting the phase-transfer reaction quench into 5 volumes of ice-cold 1M aqueous citric acid, performing extractive workup with isopropyl acetate, and concentrating the organic layer under reduced pressure at <35°C jacket temperature in a wiped-film evaporator to avoid thermal lactone re-closure or γ-elimination. The penultimate intermediate—a linear amino acid possessing a free carboxylic acid and an allylated amide nitrogen—undergoes macrocyclization via Mukaiyama reagent activation to form the 15-membered macrocyclic core characteristic of the approved direct-acting antiviral agent. Pilot-plant data from 500 L campaigns indicates 72–78% isolated yield over the two-step N-alkylation/lactone-opening sequence with a single recrystallization from ethyl acetate/hexane (1:3 v/v) delivering >99.0% HPLC purity at 215 nm. A documented incompatibility exists with sodium hydroxide as a replacement for potassium carbonate; the former accelerates Boc deprotection at the liquid-liquid interface by a factor of 3.2 based on kinetic profiling conducted in an EasyMax 102 automated reactor workstation.

Supplementing reaction progress monitoring with in-process chiral HPLC using a Chiralpak AD-H column (4.6 × 250 mm, 5 μm) and an n-hexane/ethanol/diethylamine (90:10:0.1) mobile phase at 1.0 mL/min enables quantification of the undesired diastereomer arising from γ-lactone ring-closure under acidic workup conditions. This impurity, when carried forward, generates a macrocyclic epimer separable only by preparative supercritical fluid chromatography on a Chiralcel OJ-H (30 × 250 mm) stationary phase with 15% methanol-modified carbon dioxide, incurring a yield penalty of 8–12% that renders the overall process uneconomical below the 55% cumulative yield threshold stipulated in the target product profile.

N-Boc Deprotection Kinetics in Continuous Flow for Peptide Isostere Assembly

Incorporation of this chiral lactone-pyrrolidinone into the backbone of a hydroxyethylamine transition-state isostere—a core motif in β-secretase (BACE1) inhibitor candidates examined for Alzheimer's disease modulation—commences with quantitative removal of the Boc group under continuous flow conditions optimized to minimize epimerization at the C-3 isopropyl-bearing stereocenter. The neat viscous oil obtained after solvent stripping (Brookfield viscosity 3,200 cP at 25°C) is dissolved to 0.25 M in dichloromethane and flowed through a 1.0 mm ID PFA tubular reactor coil immersed in a 50°C water bath with an in-line back-pressure regulator set to 1.7 bar. Trifluoroacetic acid (3.0 eq) is introduced via a T-mixer positioned 15 cm upstream of the residence coil, generating a residence time of 90 seconds sufficient for quantitative deprotection as verified by inline FTIR monitoring of the Boc carbonyl signal decay. The liberated secondary amine is immediately trapped in a downstream scavenger column packed with polymer-supported carbonate resin to prevent re-addition of trifluoroacetic acid during solvent swap operations. Regulatory oversight aligns with ICH Q11 principles for starting material justification, wherein the isolated deprotected intermediate is controlled to 0.15% residual trifluoroacetic acid by ion chromatography (USP <1065>) before entering the peptide coupling stage. The subsequent amide bond formation with a Boc-protected amino acid chloride—generated in situ from the corresponding acid and 1-chloro-N,N-2-trimethyl-1-propenylamine—yields a fully protected dipeptide isostere that is elaborated through an additional 6–8 synthetic steps into the final BACE1 inhibitor molecule. Production records from campaigns executed in a KiloFlow system with 100 mL/min maximum total flow rate indicate 0.6 kg/hour throughput for the deprotection segment, a rate limited not by intrinsic chemistry but by the dissipation of exothermic neutralization load in the downstream resin bed at scales exceeding 5 kg input material per batch.

A critical threshold emerges in the selection of the acid-labile protecting group for the pyrrolidinone nitrogen. When formic acid is substituted for trifluoroacetic acid to permit in-line evaporation of the deprotection reagent, the deprotection rate constant at 50°C decreases by a factor of 4.7, requiring residence time extension to 7 minutes, during which interval lactone hydrolysis arising from residual water in the formic acid (0.5–1.0% typical specification) climbs to 1.1–1.5%, breaching the 0.5% impurity threshold for advancement. This kinetic trade-off is documented across 23 development batches in the technical transfer report and reinforces the selection of anhydrous trifluoroacetic acid despite the added complexity of the post-reactor scavenging unit operation.

Lyophilization of the deprotected amine as its hydrochloride salt from a 20% aqueous acetonitrile solution at shelf temperatures ramped from −40°C to +25°C over 18 hours under 50 mTorr vacuum produces a free-flowing white powder with residual water content <1.2% by Karl Fischer titration. The material is packaged under nitrogen in double LDPE bags within sealed aluminum-laminate pouches and stored at −20°C for extended campaigns, as the free amine form demonstrates 2.1% oxidative degradation over 30 days at 5°C compared to <0.1% for the Boc-protected precursor over the identical interval, confirming the necessity of just-in-time deprotection scheduling in multi-step API manufacturing sequences.

Asymmetric α-functionalization via the Seebach self-regeneration of stereocenters methodology

When this N-Boc lactone-pyrrolidinone is enolized with lithium diisopropylamide (1.05 eq) in THF at −78°C under argon atmosphere in a jacketed 200 L glass-lined reactor equipped with a retreat-curve impeller, the resultant chiral enolate undergoes diastereoselective alkylation with benzyl bromomethyl ether (1.2 eq) to install a protected hydroxymethyl group at the pyrrolidinone α-position with >20:1 diastereomeric ratio as determined by ¹H NMR integration of the C-5 methine proton. The addition ratio is specified at 1.0 mol substrate per 8.0 L anhydrous THF to ensure homogeneous enolate formation; concentrations exceeding 0.15 M result in precipitation of the lithium enolate as a poorly stirrable slurry that retards alkylation kinetics and generates 3–5% dialkylation byproduct. Compliance with FDA 21 CFR Part 211 requires dedicated stainless steel charging lines for the alkylating agent due to its lachrymatory properties, with area monitoring badges worn by operators to document benzyl bromide vapor below the 0.5 ppm occupational exposure limit. The downstream process involves quenching into saturated aqueous ammonium chloride at 0–5°C, phase separation, THF distillation under vacuum at <30°C, and crystallization of the alkylated product from warm n-heptane (60°C dissolution, cooling to 5°C over 6 hours) to give a crystalline solid with 98.5% diastereomeric purity in 85–89% corrected yield. This alkylated intermediate serves as the chirality source for constructing the all-carbon quaternary stereocenter found in certain orally bioavailable renin inhibitors that entered Phase II clinical evaluation for treatment-resistant hypertension. An operational incompatibility documented during technology transfer involves replacement of benzyl bromomethyl ether with methoxymethyl chloride; the latter's diminished electrophilicity shifts the alkylation rate constant downward by an order of magnitude, requiring warming to −40°C at which temperature competitive proton transfer erodes diastereoselectivity to 8:1 and renders the crystallization insufficient for achieving the 99.0% purity specification.

Continuous processing via a Corning Advanced-Flow G1 silicon carbide reactor (2 mL internal volume per plate, 6 plates) allows the enolate generation and alkylation to be telescoped without intermediate isolation. The substrate and LDA streams are precooled to −78°C in separate heat exchange modules and combined at a flow rate corresponding to a 30-second residence time for quantitative deprotonation before intersecting the alkylating agent stream in a subsequent mixing zone with 90-second additional residence. This configuration reduces overall batch cycle time from 8 hours to 45 minutes per 1.0 kg input while suppressing the dialkylation impurity to <0.8% through precise residence time distribution control unattainable in batch vessels where localized alkylating agent excess generates impurity spikes during the addition period.